Clinical trials: Facial Dermatoses
Actinic Keratosis
A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities
The purpose of this trial is to evaluate the safety of a simultaneous treatment regimen compared to a sequential treatment regimen when two separate areas with AKs (one located on face/scalp and the other located on trunk/…
- Trial name
- NCT01787383
- Testing
- Ingenol mebutate gel 0.05 %, Ingenol mebutate gel 0.015 %
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- LEO Pharma
Acne Scars - Mixed Atrophic and Hypertrophic, Acne
Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring
This single-center, clinical trial consists of a one autologous fat grafting treatment followed by 3-month and 6-month post-treatment visits in order to assess the efficacy of fat grafting when used by men and women with facial…
- Trial name
- NCT04559022
- Testing
- Fat Grafting
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Acne Vulgaris
A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products
This study is to see if there's any difference in the amount of facial irritation when two acne products are used together on one side of the face, compared to one acne treatment product used alone on the other side of the face.
- Trial name
- NCT01313728
- Testing
- Dapsone plus Tretinoin Gel, Tretinoin Gel
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Acne Vulgaris
Study of Two Different 10.0% Benzoyl Peroxide Creams for Mild to Moderate Acne Vulgaris
This study is a split face, paired-comparison, pilot study of 10 subjects. Participants in this study will be patients seen at Children's Memorial Hospital, who are clinically diagnosed with mild to moderate acne vulgaris.
- Trial name
- NCT00787943
- Testing
- Topical benzoyl peroxide 10.0% cream - Formulation 1, Topical benzoyl peroxide 10.0% cream - Formulation 2
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Facial Dermatoses, Seborrheic Keratoses
Dermatosis Papulosa Nigra
DPN is a disorder among darkly pigmented patients, manifested by small, benign, variants of seborrheic keratoses, predominantly on the face.
- Trial name
- DPN (NCT00710203)
- Testing
- Pulsed dye laser, Curettage, Electrodesiccation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, Davis
Hereditary Angioedema
Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks
HAE is a rare disorder characterized by functional C1 esterase inhibitor deficiency. If not treated adequately, the acute attacks of HAE can be life-threatening and may even result in fatalities, especially in case of swelling of…
- Trial name
- NCT00168103
- Testing
- C1 Esterase Inhibitor
- Where
- 36 sites in United States, Argentina and 13 more
- Volunteers
- 126 people
- Sponsor
- CSL Behring
Acne Vulgaris
A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris
A single-blind (investigator-blinded), randomized, parallel group, single center study to evaluate the tolerability and efficacy of combination therapy with Duac Gel / 0.1% Tazorac Cream and Acanya Gel / 0.1% Tazorac Cream for…
- Trial name
- C0000-411 (NCT01016977)
- Testing
- Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene, clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
- Volunteers
- 40 people
- Sponsor
- Stiefel, a GSK Company
Actinic Keratosis
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
To determine the comparability of the safety and efficacy of Imiquimod Cream, 3.75% and Zyclara (imiquimod) Cream, 3.75% (the reference listed drug) in subjects with actinic keratosis (AK) of the face or balding scalp.
- Trial name
- NCT01686152
- Testing
- Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
- Where
- 23 sites in United States
- Volunteers
- 589 people
- Sponsor
- Teva Pharmaceuticals USA
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608476
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 52 sites in United States, Bulgaria and 4 more
- Volunteers
- 732 people
- Sponsor
- Cassiopea SpA
Actinic Keratosis
A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00916006
- Testing
- PEP005 Gel, Vehicle gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 269 people
- Sponsor
- Peplin
Rosacea
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT01318733
- Testing
- CD07805/47 gel 0.5%
- Where
- 27 sites in United States
- Volunteers
- 449 people
- Sponsor
- Galderma R&D
Actinic Keratoses
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.
- Trial name
- NCT00786994
- Testing
- Oleogel-S10 100 mg/g
- Where
- 6 sites in Germany, Greece
- Volunteers
- 165 people
- Sponsor
- Birken AG
Rosacea, Wrinkles
Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea
This study is designed to evaluate the efficacy and safety of the Luxe™ device for use in wrinkle and rosacea treatment. Up to 60 subjects will treat their periorbital and cheek areas daily for 4 weeks and then twice a week for…
- Trial name
- NCT01618864
- Testing
- Luxe
- Where
- 2 sites in United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Acne
Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne
The purpose of the study is to determine the development of microbial resistance when using one of two topical acne therapies for the treatment of facial acne vulgaris.
- Trial name
- NCT00841776
- Testing
- Duac, Ziana gel
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Stiefel, a GSK Company
Acne Vulgaris
A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)
The primary objective of this study is to determine the safety and efficacy of CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.
- Trial name
- NCT02608450
- Testing
- CB-03-01 cream, 1%, Vehicle cream
- Where
- 54 sites in United States, Georgia and 1 more
- Volunteers
- 708 people
- Sponsor
- Cassiopea SpA
Seborrheic Keratosis
A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis
This is a randomized, double-blind, vehicle-controlled, parallel group study.
- Trial name
- SK (NCT02667275)
- Testing
- A-101 Solution, Vehicle Solution
- Where
- United States
- Volunteers
- 487 people
- Sponsor
- Aclaris Therapeutics, Inc.
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Rosacea
A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
A Randomized, Double-blind, Parallel-group, Three-arm, Placebo-controlled, Multi-Site Therapeutic Equivalence Study with Clinical End-points Comparing Test Product "Oxymetazoline hydrochloride Cream, 1%" to Reference Product…
- Trial name
- NCT03954444
- Testing
- Oxymetazoline Hydrochloride, Rhofade Cream, 1%
- Where
- United States
- Volunteers
- 1,105 people, healthy volunteers welcome
- Sponsor
- Actavis Inc.
ACTINIC KERATOSIS
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.015% to Picato gel, 0.015% by establishing the therapeutic comparability of the two active products and the…
- Trial name
- NCT03200912
- Testing
- Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
- Where
- 23 sites in United States
- Volunteers
- 507 people
- Sponsor
- Actavis Inc.